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versus those with associated MH. This analysis establishes the representativeness 
of the MIVI-TRUST patient population in the context of clinical practice.
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AtoPic DermAtitiS: evAluAtion of 2 Different Drug relAteD 
mAnAgementS
Taieb C.
CREES PFSA, Paris, France
Objectives: Atopic Dermatitis (AD) is a chronic relapsing skin condition and one 
of the most common skin diseases worldwide. Nowadays, the prevalence of AD is 
estimated to be between 5%-and-30% in children. AD onset is commonly before 
5years old in children. Therapeutic treatments include topical corticosteroids (CS) 
and long-term emollients as first-line therapy, followed by topical calcineurin inhibi-
tors. Emollients represent one of the cornerstones of treatments for patients with 
AD. The aims of this study were to compare the drug related management and 
the drug related costs between children with AD treated by at least an emollient 
(composed-of-Glycerol [15 gr], Vaseline [8 gr] and liquid-paraffin [2gr] per 100 gr) 
and children not treated by emollient. MethOds: This was a retrospective analysis 
of data extracted from the “Disease Analyzer™” database, including anonymized 
data from medical files of the patients seen by a representative sample of FrenchGP. 
Children with AD diagnosed before 1 year old were tracked for 12-months after the 
date of diagnosis. Only children monitored at least 1 year after the diagnosis were 
included in the analysis. Costs of AD treatments were calculated from a societal 
perspective. Results: 49 children with AD were treated by the emollient (group 1) 
and 59 were not (group 2). 59.2% of children of group 1 were treated by CS vs 72.9% in 
group 2; the same trend was found for the prescription of antiseptic (24.5%-vs-27.1%) 
and antibiotic (10.2%-vs-13.6%). On the contrary, healing was more prescribed in the 
emollient group (32.7%-vs-25.4%). Average annual cost of prescribed dermatological 
drugs was estimated to be 139.8 € in the emollient group and 146.4 € in the other 
group. cOnclusiOns: These preliminary results suggest that CS, which may have 
negative effects (skin fragility, infection, addiction and impact on growth), are less 
prescribed in the emollient group. Studies considering larger samples are warranted 
to confirm this trend.
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Objectives: Limited data is published on baseline characteristics of patients diag-
nosed with vitreomacular traction (VMT) or different macular hole (MH) stages. Aim 
of our study was to describe the baseline patient and ocular characteristics, and 
the management of patients diagnosed with diseases of the vitreomacular inter-
face. MethOds: This was an observational study with retrospective design. The study 
sample included patients from a large tertiary care ophthalmology center in Flanders, 
who had at least 1 outpatient visit at the study center between July 2009 and May 
2013. Patients presented with or without visual symptoms and were examined using 
optical coherence tomography (OCT) in both eyes. Patients diagnosed with other 
retinal diseases were excluded from this study. This analysis reports on the VMT 
cohort only. Results: The study sample included a total of 509 patients of which 
156 patients (191 eyes) presented with VMT. Mean (SD) age was 72.8 (9.8); 59% were 
female. Majority (73%) was referred by an ophthalmologist for symptoms of general 
vision loss (60%) and/or metamorphopsia (23%). Mean follow-up was 1.64 years. Eyes 
in which a vitrectomy was performed (n= 41) presented with worse visual acuity 
(VA) compared with eyes managed through observation (0.43 versus 0.55; p= 0.029). 
However, VA in fellow eye was significantly better in eyes managed with vitrectomy 
(0.7 versus 0.56, p= 0.039). Metamorphopsia (61% versus 37%, p= 0.005) and concomi-
tant ERM (20% versus 9%, p= 0.049) were significantly more prevalent in eyes man-
aged through vitrectomy compared with observation. cOnclusiOns: In a real-life 
population, visiting the outpatient clinic of a large tertiary care ophthalmology center, 
31% of patients presented with VMT. Patients were predominantly managed though 
observation. Worse visual acuity of fellow eye, and presence of metamorphopsia or 
ERM were significantly associated with occurrence of vitrectomy.
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Objectives: To assess the diseases associated with AD or that take over during 
the years following the diagnosis of the infant and to calculate the annual cost of 
treating these children. MethOds: The cohort includes infants with AD who have 
undergone consultation with their general practitioners between the beginning of 
2000 to the end of 2003. The data gathered through the IMS database was entered by 
general practitioners, enabling tracking of patients. The tracking period was started 
after diagnosis. Only infants who were monitored for a minimum of one-year were 
included. A control group comprising infants without AD and who were monitored 
for at least a year was created. Results: A total of 723 infants who met the criteria 
outlined were identified. In the first year following their birth, infants with AD had 
significantly more concomitant disorders, particularly respiratory disorders (85% 
vs. 76%), and asthma (8.9% vs 4.6%) or other types of dermatosis (46.9% vs. 28.2%) 
among others. During the nine-years of monitoring, the children of the AD cohort 
consumed more dermatological products than the children of the control-group did 
in terms of emollients or topical corticosteroids. As well, the AD group consumed 
more antiseptic products than the control group did in the first year (27.6% vs 14%). 
Children with AD were observed to consume more anti-asthma drugs, with a peak 
occurring at age 4. cOnclusiOns: From an epidemiological perspective, this study 
Objectives: The main aims of this systematic review were to identify all relevant 
literature on clinical efficacy for biological medications in patients with psoriasis 
and to conduct an up-to-date meta-analysis. MethOds: The following compara-
tors were considered for this analysis: adalimumab, etanercept, infliximab, and 
ustekinumab. A MEDLINE search was conducted until March 2013. The Cochrane 
Highly Sensitive Search Strategy was applied to identify randomized controlled 
publications and was combined with ‘psoriasis’ MeSH terms and drug names. 
Randomized, controlled, clinical trials with adults with moderate-to-severe pso-
riasis where the full paper can be obtained were included. Evidences were com-
bined in a mixed treatment comparisons in a Bayesian framework. Efficacy was 
measured by the 75% and 90% improvement of Psoriasis Area Severity Index (PASI) 
at three months were analysed. Results: Nineteen trials were included in this 
indirect comparison; treatment arms with off-label dosages were excluded. Each 
biologic showed significantly more favourable effect than placebo with respect to 
any level of PASI response. Significantly more patients on infliximab treatment 
met PASI75 endpoint than on etanercept, adalimumab or ustekinumab, combined 
odds ratios (95% confidence intervals) were 5.34 (2.29-12.50), 7.49 (3.31-16.92) and 
3.64 (1.62-8.20) respectively. Similarly, significantly more patients on infliximab 
treatment met PASI90 endpoint than on adalimumab or etanercept, odds ratios 
were 6.12 (1.07-34.86) and 7.78 (1.02-59.01). No significant differences in terms of 
PASI75 and PASI90 improvements were observed between adalimumab, etanercept 
or ustekinumab. cOnclusiOns: All biologics demonstrated statistically significant 
improvements compared to placebo. This review also showed that infliximab was 
significantly more efficacious than other biologics.
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Objectives: To evaluate the comparative effectiveness of bimatoprost 0.03%/
timolol (BTFC) 0.5% preservative-free (PF) fixed combination solution in single 
dose vials (BTFC PF) for the treatment of glaucoma/ocular hypertension (OHT) 
compared to alternative combination therapies accounting for fluctuations in 
intraocular pressure (IOP). MethOds: A systematic review was conducted to iden-
tify randomised controlled trials investigating efficacy of combination therapies 
for the treatment of glaucoma/OHT; where efficacy is defined as IOP change from 
baseline. Maximum and minimum changes in IOP were used as a representa-
tion of peak and trough effects of medication. Prostaglandin/prostamide analog 
and timolol monotherapy trials were also included as key connectors. A Bayesian 
mixed treatment comparison (MTC) analysis was used to synthesise the resulting 
evidence base. Supportive probability of best and rankogram summary analysis 
were used to position treatments within the network based on efficacy. Results: 
A total of 136 studies met the pre-determined MTC inclusion criteria in total; 
representing 24 unique treatment arms. BTFC PF was numerically superior to all 
treatments (monotherapies and combination therapies; preserved and PF thera-
pies) in lowering IOP efficacy in both peak and trough analyses. This superiority 
was statistically significant (p< 0.05) for 18/23 comparisons in both analyses. Lack 
of evidence is the likely reason for non-significance in remaining comparisons. The 
probability of the BTFC formulations (preserved or PF) being the best treatments 
in the network was 0.94 (94% chance) in the peak analysis and 0.90 (90% chance) 
in the trough analysis; BTFC PF specifically had a 57% chance in the peak analysis 
and 62% chance in the trough analysis. No other treatments had > 6% chance. 
Overall ranking of BTFC PF and BTFC preserved in terms of IOP-lowering efficacy 
was 1st and 2nd respectively. cOnclusiOns: BTFC PF showed the greatest clinical 
efficacy of any combination- or mono-therapy in reducing IOP from baseline in 
patients with glaucoma and/or OHT.
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Objectives: There is limited published evidence on demographic and vitreoretinal 
interface (VRI) characteristics of patients with vitreomacular traction (VMT), includ-
ing when associated with macular hole (VMT+MH). Establishing insights into the 
characteristics of untreated VMT patients may contribute to a better understanding 
of the burden of VMT disease. The objective of our analysis is to describe baseline 
patient characteristics and VRI features in patients with persistent VMT included in 
the phase 3 ocriplasmin studies. This analysis reports on VMT patients without MH 
(VMT) and VMT patients with MH (VMT+MH). MethOds: Two randomized, double-
masked, placebo-controlled trials designed to determine efficacy and safety of ocri-
plasmin for the treatment of VMT comprising of 652 patients (VMT n= 499; VMT+MH 
n= 153). Baseline characteristics included patient demographics (age, gender); eye-
disorder characteristics (time since diagnosis, visual acuity (VA) in study eye (SE); VA 
in non-study eye (NSE), presence of pseudophakia and/or ERM; VRI features (focal 
adhesion ≤ 1500 microns; min-max MH width), VFQ-25 composite score. Results: 
Baseline characteristics for VMT vs. VMT+MH patients were respectively: 72.6 ver-
sus 68.7 years; 62.7% versus 75.8% female. Time since diagnosis: 268 days versus 
62 days; VA: SE 66.8 versus 55.9, NSE 73.5 versus 77.8. Pseudophakes: 38.7% ver-
sus 20.9%, concomitant ERM: 46.3 % versus 15.8%. The majority of VMT patients 
presented with focal adhesion ≤ 1500 microns (69%) while VMT+MH patients pre-
sented with a min-max hole width of 272.7 microns. VFQ-25 composite score: 78.0 
vs. 80.3. cOnclusiOns: Baseline characteristics of the MIVI-TRUST ocriplasmin 
patient population show differentiations between patients with persistent VMT 
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(vPDT) fell from 93% to 68%. In the ‘without ranibizumab’ scenario, only vPDT was 
administered. Costs of treatment, administration, monitoring, bilateral disease and 
management of recurrences were included. Results: An estimated 2045 patients 
were eligible for treatment at year 1 and 2119 at year 5. In the ‘with ranibizumab’ 
scenario, 143 patients received ranibizumab at year 1, increasing to 678 at year 5; 
1902 patients received vPDT at year 1 and 1441 at year 5. ‘With ranibizumab’ annual 
costs were higher in years 1–2 than ‘without ranibizumab’ costs. During years 3, 
4 and 5, cost savings occurred with ranibizumab (£3867, £121 584 and £232 467, 
respectively), owing to lower total costs of treatment and monitoring than with 
vPDT. The total 5-year saving ‘with ranibizumab’ over ‘without ranibizumab’ was 
£227 086. cOnclusiOns: Treating visual impairment due to CNV secondary to PM 
with ranibizumab rather than vPDT is estimated to provide significant cost savings 
in England and Wales over 5 years.
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Diabetic retinopathy (DR) is one of the main reasons of vision loss. Traditional 
treatment provides insufficient control of disease and adverse events. New drug 
ranibizumab usage in treatment of DR opens new opportunities in treatment of DR. 
Objectives: To provide pharmacoeconomic assessment of ranibizumab in DR treat-
ment in the Russian Federation. MethOds: Comparative modeling cost-effective-
ness (CEA) and budget impact (BIA) analyses based on clinical trials results were 
conducted. CEA with 1 year time horizon for basic group patients and BIA with 
5 year time horizon for high risk vision loss patient group. CEA considered only 
direct costs (DC), while BIA dealt with both DC and indirect costs (IC). 1 EURO = 40 
RUB. Results: Annual total costs (TC) per patient (PP) for ranibizumab treatment (8 
injections on the average) approached 9786 EURO. Annual TC for LC treatment were 
440 EURO PP. Ranibizumab provides 6,1 letters vision improvement on the average, 
while LC – 0,8 letters. Cost-effectiveness ratio (CER) for ranibizumab was 1604 EURO 
per letter, for LC CER was 550 EURO per letter. ICER was 1764 EURO per additional 
letter. Second scenario included DR patients going blind in 5 years on LC treatment, 
while on ranibizumab treatment they could keep their eyesight. TC over 5 years for 
ranibizumab treatment (13 injections on the average) were 15225 EURO PP. TC over 
5 years on LC were 27327 EURO PP, including IC due to vision loss – 25250 EURO. BIA 
results have shown that ranibizumab treatment for high-risk vision loss DR patients 
group provided 9 616 EURO (discounted at 3,5%) cost-saving PP in comparison with 
LC treatment. cOnclusiOns: Ranibizumab is highly effective costly treatment 
that demands additional consideration for administration in common DR patient 
group, while it seems to be cost-saving in DR patient group of high-risk vision loss.
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Objectives: To evaluate the impact of Herpes Zoster (HZ) as associated diagnosis 
on hospitalizations for an other main health problem, using 3 evaluation crite-
ria: length of stay, number of death and cost from the national health insurance 
perspective. MethOds: The hospitalizations of people aged 50 years and more 
were selected from the French national hospital database (PMSI) 2011 using ICD 
10 diagnosis code: HZ (B02*) in associated diagnosis (DAS), and excluding codes of 
immunosuppressive conditions (D8* or B20*-B24*). The 5 main categories of diseases 
leading to hospitalization distribution allowed us to select, in decreasing order of 
importance: circulatory (I0*-I5* & I7*-I9*), respiratory (J0*-J9*), digestive (K0*-K9*), 
osteo-articular systems (M0*-M9*), and diabetes (E1*). For each of the 5 categories, a 
retrospective case-control has been realized. The cases are defined by hospitaliza-
tions with HZ in DAS and controls were hospitalizations without HZ in DAS matched 
on age and sex to the cases. Statistical non parametric analyses (Wilcoxon-Mann-
Whitney) in each of the five categories have been realized to evaluate the difference 
in length of stay, death rate, and cost. Results: In each of the five categories, cases 
presented a statistically significant length of stay compared to the controls. Median 
differences varying of 3 days for osteo-articular system (+50%) to 6 days for diges-
tive system (+300%). None difference in the death rates has been observed. The 
study also demonstrated a statistically significant cost of cases compared to the 
controls median differences varying of 857€ for circulatory system (+25%), 922€ for 
osteo-articular system (+26%), 945€ for respiratory system (+26%), 987€ for diabetes 
(+39%), and 2011€ for digestive system (+126%). cOnclusiOns: When present as 
an associated diagnosis in hospitalizations of people 50+ for other medical reasons, 
HZ significantly increases the length of stay at hospital and subsequent economic 
burden for the French health system.
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Objectives: The aim of this study was to compare spectacle independence and 
vision-related quality of life following implantation of a multifocal intraocular 
lens (IOL: ReSTOR®) or monofocal IOLs. MethOds: This prospective observational 
study involved 206 cataract surgery patients (median age 71 years, range 51–90 
years) receiving either the multifocal IOL or monofocal IOLs. The primary outcome 
measures were the proportion of patients with a postoperative improvement in 
uncorrected visual acuity of 0.1 logMAR or better, the proportion of patients achiev-
ing spectacle independence, and vision-related quality of life assessed using the 
was in line with current data. Pulmonary symptoms call for vigilance in monitoring 
children. Chronic ocular inflammation sometimes is the cause of long-term cata-
racts in patients with atopic disorders. Early ocular symptoms found in this cohort 
must be specified and suggest that an opthamological follow-up may be required 
in some cases. In addition, the abnormally high consumption of antiseptics - and 
also often the source of irritation - raises concerns about children’s treatment.
PSS7
BurDen of Actinic kerAtoSiS in germAny-reSultS of A literAture 
reSeArch
Pfiffner C.1, Macheleidt O.2, Batscheider A.1, Ehlken B.1, Greiner R.A.1, Schroeder C.1, Hutt H.J.2
1IMS Health, Munich, Germany, 2LEO Pharma GmbH, Neu-Isenburg, Germany
Objectives: Actinic keratoses (AK) are dermatological conditions with the risk-
potential becoming squamous cell carcinoma (SCC). Descriptions of AK-epidemiology 
and cost-of-illness are currently necessary when submitting an AMNOG dossier for an 
AK-product in Germany. MethOds: To describe AK-epidemiology a targeted litera-
ture research was conducted in PubMed in 2012, using the search terms (epidemiology 
OR incidence OR prevalence). To find relevant cost-of-illness information the following 
search terms were used (cost OR costs OR burden OR econom* OR pharmacoeconom* 
OR financ* OR budget OR reimburs* OR (resource NEAR (use OR utilization))). Both 
searches were combined with AND ((actinic OR solar OR senil*) AND (keratos* OR 
cheilitis)) AND Germany. PubMed research was supplemented by additional searches 
in guidelines and the World Wide Web for publications in German/English. Results: 
The screening of the epidemiology results (36 in PubMed) identified two relevant 
publications of four studies investigating AK-prevalence in Germany (Schäfer epub 
ahead of print 2012, Lichte 2010). An additional search for the German phrase “nicht 
melanozytäre Hautkarzinome” identified a publication on the cost-benefit of skin-
cancer-screening, including data on prevalence of AK (Guther 2011). The study results 
demonstrate a prevalence range between 2.0% and 7.4% with increasing prevalence 
by age. So far no cost-of-illness data of AK were identified for Germany (5 hits in 
pubmed). In an expert survey from Augustin and Kornek (2012) one important cost-
factor was seen in the progression of AK into SCC and its prevention might reduce 
treatment cost and burden of disease for patients. Citation tracking of this expert-
survey identified an additional prevalence-study in Germany (prevalence 2%, Augustin 
2011). cOnclusiOns: No data of AK-incidence in Germany are available. Prevalence 
data of AK in Germany have a broad range from 2.0% - 7.4%. Cost-of-illness data are 
needed for Germany to demonstrate the cost saving aspect of AK-prevention as seen 
in cost-of-illness studies of other countries.
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Objectives: In Europe only few and inconsistent data on the prevalence and 
treatment of Actinic Keratoses (AK) are available. Objective of this study was to 
determine the prevalence of AK in Germany, to identify potential predictors and to 
estimate the number of AK cases treated in dermatologic practices. MethOds: In a 
multiple-source-approach, prevalence was assessed from whole-body-examinations 
in a cohort of 90.800 employees and from nationwide statutory health insurance 
(SHI) data of 2008. c) The number of cases documented in dermatological offices was 
estimated from statistics of a SHI Physicians Association. Results: Standardized 
prevalence of AK from dermatological examinations was 2.7%; the rate increased 
with age (11.5% in the group 60-70 years) and was higher for men (3.9%) than for 
women (1.5%). Significant associations were also identified for skin phototype I, 
sunburns in childhood and solar lentigines. Vitiligo and a history of melanoma were 
also but not significantly associated with AK. In the SHI data analysis standardized 
AK prevalence was 1.8%. Age-specific rates were below 1.5% up to 60 years and rose 
to 8.2% (13.2% in men) in the group 80-89 years. The prevalence from these large 
data sets - which is at the lower limit of studies from other countries – suggests 
about 1.7 Mio. estimated AK cases in Germany. In 2011 AK accounted for 8.3% of the 
hundred most frequently treated dermatological outpatient diagnoses. The propor-
tion of AK cases has risen almost continuously over the last 10 years. Estimated 
annual number of AK cases documented by dermatologists in Germany is about 
1.7 Mio. cOnclusiOns: AK is a frequent condition in higher age groups and more 
prevalent in men; a relevant need for health care evident. Predictors and risk factors 
for AK are easy to identify in the population, which could also help to detect groups 
with special need for preventive measures.
SenSory SyStemS DiSorDerS – cost Studies
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the BuDget imPAct of introDucing rAniBizumAB in englAnD AnD 
wAleS for the treAtment of viSuAl imPAirment Due to choroiDAl 
neovASculArizAtion SeconDAry to PAthologic myoPiA
Malcolm W.A.1, Leteneux C.2, Claxton L.3, Taylor M.3, Rathi H.4
1Novartis UK, Frimley, UK, 2Novartis Pharma AG, Basel, Switzerland, 3York Health Economics 
Consortium, York, UK, 4Novartis Healthcare Pvt.Ltd., Hyderabad, India
Objectives: To evaluate the budget impact of introducing ranibizumab. MethOds: 
Cumulative costs were assessed using an open cohort model with a 5-year time 
horizon and NHS perspective. The number of eligible patients was based on: the 
estimated prevalence of pathologic myopia (PM) in the population > 40 years old 
(1.2%); the incidence of choroidal neovascularization (CNV) in patients with PM 
(0.98%); the proportion of patients eligible for pharmacotherapy (81%) and bilateral 
disease prevalence (5.5%). Treatment and diagnosis rates were estimated at 80% and 
83–86% respectively. Treatment frequency was based on RADIANCE trial data. The 
model compared two scenarios. In the ‘with ranibizumab’ scenario, the proportion 
of eligible patients treated with ranibizumab was estimated as 7% at year 1, increas-
ing to 32% at year 5; the proportion receiving verteporfin photodynamic therapy 
